Akero Therapeutics Reveals New Results from SYMMETRY and HARMONY Trials

Trial Findings: Akero Therapeutics presented new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin for patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH), to be shared at the AASLD Liver Meeting 2025.

Efruxifermin Efficacy: The 96-week data from the SYMMETRY trial showed that efruxifermin significantly improved portal hypertension risk and noninvasive measures of fibrosis compared to placebo, indicating its antifibrotic activity.

AI-Assisted Evaluation: Liver biopsies analyzed using AI-assisted digital pathology confirmed the improvements in fibrosis associated with efruxifermin, showing consistent reductions in total fibrosis and septa area, which are critical indicators of cirrhosis severity.

Clinical Implications: The findings suggest that efruxifermin may reduce the risk of liver-related complications in patients with cirrhosis, highlighting its potential as a therapeutic option for managing this condition.